SEC Tracker
Get the app

Inhibikase Therapeutics IKT

Inhibikase Therapeutics announces Q3 2026 results

Inhibikase Therapeutics (IKT) filed an 8-K with the SEC on Nov 10, 2026, 4:28 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Regulatory approvals for 28 countries in IMPROVE-PAH trial
  2. 79 of 180 clinical sites activated in trial
  3. Raised $50 million from RA Capital in July 2026
  4. FDA granted Orphan Drug Designation for IKT-001

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Inhibikase Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.